T. Jia

miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1

Jianbo Zheng, Botao Xu, Yinping Sun, 2016, Bioscience reports.

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Y. Ba, S. Qin, Likun Liu, 2018 .

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Y. Ba, S. Qin, Likun Liu, 2018 .

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Wei Li, F. Gao, Y. Ba, 2023, BMC Medicine.

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

Y. Ba, M. Tao, S. Qin, 2018 .